Using annexinV/PI dual staining and western blot analysis with cell death markers, we have shown that the combination therapy is effective in a p53-dominant negative genetic background and also overcomes cisplatin resistance in lung cancer cells. Here, ANXA5 is linked to lung carcinoma.